Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Structured Treatment of Gastroesophageal Reflux in a Company Health Care Setting, -Effect on Quality of Life, Symptoms and Productivity

This study has been completed.
Information provided by:
AstraZeneca Identifier:
First received: April 17, 2009
Last updated: December 6, 2010
Last verified: December 2010
The study aims to evaluate if a GERD treatment programme, in accordance with current regional recommendations, in a company health care setting, has an impact on health related quality of life (HRQoL), symptoms, and productivity in GERD patients.


Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: A Prospective, Non Interventional Study to Evaluate the Effects on Quality of Life, Symptoms and Productivity in Patients With Gastroesophageal Reflux Disease (GERD) After 6 Weeks Structured Treatment in a Company Health Care Setting

Resource links provided by NLM:

Further study details as provided by AstraZeneca:

Enrollment: 36
Study Start Date: April 2009
Study Completion Date: June 2009

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Company health care setting

Inclusion Criteria:

  • Female and/or male aged > 18 years
  • Diagnosis of GERD confirmed
  • Prescription of GERD treatment or already receiving GERD treatment

Exclusion Criteria:

  • Any symptom suggesting a need for further investigation
  • Previous participation in the present study
  • Current participation in a clinical study or participation in a clinical study during the last 30 days
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00884247

Research Site
Hälsocenter, Södertälje, Sweden
Sponsors and Collaborators
Study Director: Svante Sjöstedt, MD, PhD AstraZeneca Sweden
Principal Investigator: Dan Regberg, MD AstraZeneca Sweden
  More Information

Responsible Party: Svante Sjöstedt/MC MDOTA, AstraZeneca Identifier: NCT00884247     History of Changes
Other Study ID Numbers: NIS-GSE-DUM-2009/1 
Study First Received: April 17, 2009
Last Updated: December 6, 2010
Health Authority: Sweden: Regional Ethical Review Board

Keywords provided by AstraZeneca:
Quality of life
Structured treatment

Additional relevant MeSH terms:
Gastroesophageal Reflux
Esophageal Motility Disorders
Deglutition Disorders
Esophageal Diseases
Gastrointestinal Diseases
Digestive System Diseases processed this record on October 25, 2016